Peer review is the evaluation of work by one or more people with similar competences as the producers of the work (peers). It functions as a form of self-regulation by qualified members of a profession within the relevant field. Peer review methods are used to maintain quality standards, improve performance, and provide credibility. In academia, scholarly peer review is often used to determine an academic paper's suitability for publication. Peer review can be categorized by the type of activity and by the field or profession in which the activity occurs, e.g., medical peer review.
A medical journal is a peer-reviewed scientific journal which communicates medical information to physicians and other health professionals. Journals that cover many medical specialties are sometimes called general medical journals.
Therapy is the attempted remediation of a health problem, usually following a diagnosis. In the medical field, it is usually synonymous with treatment. Among psychologists and other mental health professionals, including psychiatrists, psychiatric nurse practitioners, counselors, and clinical social workers, the term may refer specifically to psychotherapy. The English word therapy comes via Latin therapīa from Greek: θεραπεία and literally means "curing" or "healing".
The journal is published by Informa and the Editor-in-Chief is Giuseppe Tonini, Director of Medical Oncology, University Campus Bio-Medico, (Italy). Expert Opinion on Investigational Drugs was established in 1992 and according to the Journal Citation Reports has a 2014 impact factor of 5.528. It is also indexed in MEDLINE. The journal is available online and in paper format.
Informa plc is a multinational events and publishing company with its head office and registered office in London. It has offices in 43 countries and around 11,000 employees. It owns numerous brands including CRC Press, Datamonitor, Fan Expo, Institute for International Research, Lloyd's List, Penton, Routledge, Taylor & Francis, and UBM.
Journal Citation Reports (JCR) is an annual publication by Clarivate Analytics. It has been integrated with the Web of Science and is accessed from the Web of Science-Core Collections. It provides information about academic journals in the natural sciences and social sciences, including impact factors. The JCR was originally published as a part of Science Citation Index. Currently, the JCR, as a distinct service, is based on citations compiled from the Science Citation Index Expanded and the Social Science Citation Index.
The impact factor (IF) or journal impact factor (JIF) of an academic journal is a measure reflecting the yearly average number of citations to recent articles published in that journal. It is frequently used as a proxy for the relative importance of a journal within its field; journals with higher impact factors are often deemed to be more important than those with lower ones. The impact factor was devised by Eugene Garfield, the founder of the Institute for Scientific Information. Impact factors are calculated yearly starting from 1975 for journals listed in the Journal Citation Reports.
Article categories
The journal publishes articles in the following categories:
An editorial, leading article (US) or leader (UK), is an article written by the senior editorial staff or publisher of a newspaper, magazine, or any other written document, often unsigned. Australian and major United States newspapers, such as The New York Times and The Boston Globe, often classify editorials under the heading "opinion".
This page is based on this Wikipedia article Text is available under the CC BY-SA 4.0 license; additional terms may apply. Images, videos and audio are available under their respective licenses.
Related Research Articles
Dacetuzumab is a humanized monoclonal antibody being developed for the treatment of CD40-positive cancers like non-Hodgkin's lymphoma and hematological malignancies.
Cethromycin, trade name Restanza is a ketolide antibiotic undergoing research for the treatment of community acquired pneumonia (CAP) and for the prevention of post-exposure inhalational anthrax, and was given an "orphan drug" status for this indication. Originally discovered and developed by Abbott, it was acquired by Advanced Life Sciences Inc. for further development.
Lerisetron (code name F-0930-RS) is a drug which acts as an antagonist at the 5-HT3 receptor. It is a potent antiemetic and was in clinical trials for the treatment of nausea associated with cancer chemotherapy.
Altropane, is a phenyltropane derivative which acts as a potent dopamine reuptake inhibitor and long-acting stimulant drug. It has mainly been used as the 125I radiolabelled form for mapping the distribution of dopamine transporters in the brain, and consequently this has led to its development as a potential diagnostic tool for early detection of Parkinson's disease. It is also being investigated for potential use in the diagnosis and treatment of attention deficit hyperactivity disorder (ADHD).
Cetilistat is a drug designed to treat obesity. It acts in the same way as the older drug orlistat (Xenical) by inhibiting pancreatic lipase, an enzyme that breaks down triglycerides in the intestine. Without this enzyme, triglycerides from the diet are prevented from being hydrolyzed into absorbable free fatty acids and are excreted undigested.
YM-348 is an indazole derivative drug which acts as a potent and selective 5-HT2C receptor agonist, with an EC50 of 1nM and 15x selectivity over 5-HT2A, although it only has moderate selectivity of 3x over the closely related 5-HT2B receptor. It has thermogenic and anorectic effects in animal studies, making it potentially useful for the treatment of obesity.
ABT-202 is a drug developed by Abbott, which acts as an agonist at neural nicotinic acetylcholine receptors and has been researched for use as an analgesic, although it has not passed clinical trials.
Ezlopitant (INN, code name CJ-11,974) is an NK1 receptor antagonist. It has antiemetic and antinociceptive effects. Pfizer was developing ezlopitant for the treatment of irritable bowel syndrome but it appears to have been discontinued.
Elzasonan (CP-448,187) is a selective 5-HT1B and 5-HT1D receptor antagonist that was under development by Pfizer for the treatment of depression but was discontinued, possibly due to poor efficacy. By preferentially blocking 5-HT1B and 5-HT1D autoreceptors, elzasonan is thought to enhance serotonergic innervations originating from the raphe nucleus, thereby improving signaling to limbic regions like the hippocampus and prefrontal cortex and ultimately resulting in antidepressant effects.
Tazomeline (LY-287,041) is a drug which acts as a non-selective muscarinic acetylcholine receptor agonist. It was in clinical trials for the treatment of cognitive dysfunction such as that seen in Alzheimer's disease and schizophrenia, but development was apparently scrapped for unknown reasons.
Fedotozine is an opioid drug of the arylacetamide series which acts as a peripherally-specific, selective κ1-opioid receptor agonist with preference for the κ1A subtype. It was under investigation for the treatment of gastrointestinal conditions like irritable bowel syndrome and functional dyspepsia and made it to phase III clinical trials, but ultimately development was discontinued and it was never marketed.
CC-1088 is a thalidomide analogue inhibitor of phosphodiesterase 4 that was being developed up to 2005 by Celgene Corp., for treating of inflammatory diseases and myelodysplastic syndromes. Apremilast (CC-10004) was found to be a preferable.
Selurampanel is a drug closely related to the quinoxalinedione series which acts as a competitive antagonist of the AMPA and kainate receptors and, as of 2015, is being investigated in clinical trials by Novartis for the treatment of epilepsy. It has also been studied in the acute treatment of migraine, and was found to produce some pain relief, but with a relatively high rate of side effects.
Seltorexant (former developmental code names MIN-202, JNJ-42847922, JNJ-922) is a selective, small-molecule antagonist of the OX2 receptor that is under development by Minerva Neurosciences and Johnson & Johnson's Janssen Pharmaceutica for the treatment of insomnia and major depressive disorder (MDD). As of December 2015, it is in phase II clinical trials for both insomnia and MDD.
Roluperidone (former developmental code names MIN-101, CYR-101, MT-210) is a 5-HT2A and σ2 receptor antagonist that is under development by Minerva Neurosciences for the treatment of schizophrenia. One of its metabolites also has some affinity for the H1 receptor. As of May 2018, the drug is in phase III clinical trials.
Cioteronel is a nonsteroidal antiandrogen (NSAA) that was never marketed. It was under development between 1989 and 2001 for the topical treatment of androgenetic alopecia and acne and for the oral treatment of benign prostatic hyperplasia; it reached phase III clinical trials for acne and phase II studies for androgenetic alopecia, but was ultimately discontinued due to poor efficacy.
Solriamfetol, sold under the brand name Sunosi, is a medication used for the treatment of excessive sleepiness associated with narcolepsy and sleep apnea.
Current Opinion is a series of medical journals published by Current Drugs from 1998 to 2010. Current Drugs was acquired by Thomson Reuters in 2004.
Journals in the series included:
